Non-small cell lung cancer (NSCLC) management increasingly relies on precise genomic profiling to guide therapy. While G12C is the most well-known variant, KRAS Q61 mutations NSCLC represent a distinct and heterogeneous subgroup. These mutations account for approximately 1% to 7% of all KRAS-mutant cases. Recent research now clarifies the prognostic value and treatment sensitivity of this specific cohort, providing much-needed clarity for clinicians.

Researchers analyzed diagnostic samples from over 8,000 patients using next-generation sequencing (NGS). They identified that the majority of patients presented with either Q61H (74.0%) or Q61L (20.8%) mutations. Interestingly, these subtypes demonstrate unique molecular environments. For instance, the Q61H variant frequently co-occurs with STK11, TP53, and KEAP1 mutations. Conversely, the Q61L subtype appears mutually exclusive to STK11 and shows a lower incidence of KEAP1 alterations. These differences are significant because co-mutations often dictate how a tumor responds to standard treatments.

Clinical Management of KRAS Q61 Mutations NSCLC

The study findings strongly favor immunotherapy-based regimens for this patient population. Specifically, patients receiving combined chemoimmunotherapy or immunotherapy monotherapy as first-line treatment experienced significantly prolonged progression-free survival compared to those on chemotherapy. Notably, the median overall survival for those on immunotherapy reached 65.4 months in some subsets. Furthermore, the molecular heterogeneity suggests that Q61L might behave differently from Q61H, emphasizing the need for detailed NGS reports rather than simple KRAS-positive results.

In the Indian clinical context, where lung cancer remains a leading cause of mortality, identifying these rare KRAS variants is vital. Because these patients show such a favorable response to immune checkpoint inhibitors, early genomic testing can prevent the use of less effective cytotoxic therapies. Consequently, oncologists should prioritize comprehensive molecular testing to identify KRAS Q61 mutations NSCLC and tailor first-line interventions accordingly.

How common are KRAS Q61 mutations compared to other KRAS types?

KRAS Q61 mutations are relatively rare, representing between 1% and 7% of all KRAS mutations found in non-small cell lung cancer cases.

Does the co-mutation profile affect treatment for Q61 patients?

Yes, co-mutations like STK11 and KEAP1 are more common in the Q61H subtype and are traditionally associated with different therapy responses, though this cohort generally responds well to immunotherapy.

What is the preferred first-line treatment for this mutation?

Current evidence suggests that immunotherapy, either as monotherapy or combined with chemotherapy, significantly improves survival outcomes compared to chemotherapy alone for patients with KRAS Q61 mutations.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Refer to the latest local and national guidelines for clinical practice.

References

Ruge L et al. Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring KRAS Q61 mutations to assess therapeutic responses. Clin Cancer Res. 2026 Jun 10. doi: 10.1158/1078-0432.CCR-26-0133. PMID: 42268349.

Arbour KC et al. Effects of Co-occurring KRAS, TP53, STK11, and KEAP1 Mutations on Immune Checkpoint Inhibitors in NSCLC. JAMA Oncol. 2018;4(8):e181101.

Ganesan PN et al. KRAS mutated Non-Small Lung Carcinoma: A Real World Context from the Indian subcontinent. Indian J Med Paediatr Oncol. 2022.